Marijuana craving trajectories in an adolescent marijuana cessation pharmacotherapy trial

Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, United States. Electronic address: .
Addictive behaviors (Impact Factor: 2.76). 11/2012; 38(3):1788-1791. DOI: 10.1016/j.addbeh.2012.11.003
Source: PubMed


Marijuana is the most widely used illicit substance among youths and recent epidemiological data indicate that rates of marijuana use are on the rise. The purpose of this study was to examine marijuana craving trajectories among adolescents in an eight-week, placebo-controlled pharmacotherapy trial targeting marijuana cessation. All participants received contingency management and cessation counseling, and were randomized to either N-acetylcysteine (1200mg NAC twice daily; n=45) or placebo (n=44). Craving for marijuana was measured using the short-form of the Marijuana Craving Questionnaire (MCQ). Results demonstrated a significant decrease in MCQ scores over time for the total sample, but no significant differential change in scores between the NAC and placebo groups. This lack of significant difference is in the setting of NAC participants submitting significantly more negative urine cannabinoid tests as compared to placebo participants. This suggests that cessation effects associated with NAC may be mediated by effects other than marijuana craving.

Download full-text


Available from: Nathaniel L Baker
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: There is a clear and pressing need to expand pharmacotherapy options for substance use disorders (SUDs) in order to improve sustained abstinence outcomes. Preclinical literature has demonstrated the role of glutamate in addiction, suggesting that new targets for pharmacotherapy should focus on the restoration of glutamatergic function. Glutamatergic agents for SUDs may span multiple addictive behaviors and help demonstrate potentially overlapping mechanisms in addiction. The current review will focus specifically on N-acetylcysteine (NAC), a safe and well-tolerated glutamatergic agent, as a promising potential pharmacotherapy for the treatment of SUDs across several substances of abuse. Building on recently published reviews of the clinical efficacy of NAC across a broad range of conditions, this review will more specifically discuss NAC as a pharmacotherapy for SUDs, devoting particular attention to the safety and tolerability profile of NAC, the wealth of preclinical evidence that has demonstrated the role of glutamate dysregulation in addiction, and the limited but growing clinical literature that has assessed the efficacy of NAC across multiple substances of abuse. Preliminary clinical studies show the promise of NAC in terms of safety, tolerability, and potential efficacy for promoting abstinence from cocaine, nicotine, and cannabis. Results from randomized clinical trials have been mixed, but several mechanistic and methodological factors are discussed to refine the use of NAC in promoting abstinence and relapse prevention across several substances of abuse. Further preclinical and clinical investigation into the use of NAC for SUDs will be vital in addressing current deficits in the treatment of SUDs.
    Full-text · Article · Jan 2014 · CNS Drugs
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Current marijuana use rates are the highest in the past decade and not likely to decrease given the legalization of marijuana for medicinal and/or recreational use. Concurrently, the nation is facing epidemic levels of obesity, cardiovascular disease and diabetes but little is known about the intersecting relationships of marijuana use and cardiometabolic health. The objective of this study was to explore emerging issues in context to the intersection of cardiometabolic risk and marijuana use. This topic has potential important implications for our nation's health as we relax our approach to marijuana but continue to have unacceptable rates of cardiometabolic illnesses.
    Full-text · Article · Jan 2014 · Journal of Addictive Diseases
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cannabis is the most widely used illicit drug in the world, with the highest rates of use seen in New Zealand, North America and Australia. There is evidence of a decrease in the age of commencement of cannabis use in some developed countries, and a prolongation of risk of initiation to cannabis use beyond adolescence in more recent cohorts of users. Early initiation of cannabis use and regular use during adolescence are particular risk factors for later problematic cannabis and other drug use, as well as mental health problems, delinquency, loss of cognitive capacity and educational achievement, risky sexual behavior and criminal offending. Cannabis use with tobacco complicates treatment for each condition and should be addressed concurrently. Cannabis users often have a long history of use before seeking treatment, and early screening, assessment and treatment are recommended. There are a number of valid and reliable screening and assessment tools now available. Severity of withdrawal is a factor that increases relapse, and pharmacotherapy for withdrawal management is developing rapidly and showing great promise. Finally, a combination of motivational enhancement therapy and cognitive-behavioral therapy alone or within a family systems model are the proven treatment protocols for cannabis use disorder.
    No preview · Article · Feb 2014
Show more